Oxford Genome Sciences Changes its Name to Oxford BioTherapeutics
Oxford Genome Sciences announced that it has changed its name to Oxford BioTherapeutics (OBT). The new name will take effect immediately. According to the company, the name reflects the company’s complete focus on the discovery and development of targeted antibody medicines to address large and unmet patient needs in the field of oncology.
OBT combines its in-house capabilities in the discovery of novel targets for oncology with its partners Medarex’s and Amgen’s expertise in the development of antibody therapeutics to create an exciting pipeline of innovative first-in-class therapeutics for the treatment of cancer. Through these collaborations, OBT has access to two technologies for generating fully human monoclonal antibodies. In addition, OBT has a collaboration with Biosite Inc., a wholly owned subsidiary of Inverness Medical Innovations, for the identification of novel protein-based disease markers for several cancer indications and for the development of companion diagnostic products aimed at improving the diagnosis, prognosis and treatment options for patients with cancer.
OBT’s CEO, Dr. Christian Rohlff, commented, “I am very excited by the progress we have made in developing our therapeutic antibody pipeline and the new name truly embodies the core strategic focus of the Company on the development of successful antibody-based drugs for cancer, with integrated diagnostics. The adoption of a new name comes at a key turning point in the Company’s development, as it evolves into an oncology-focussed clinical development organisation. With our collaborations with Amgen, Medarex and Biosite making significant progress, I am confident that our integrated approach to the development of antibody therapeutics and diagnostics will enable us to become an important player in the field of personalized medicines in oncology.”
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous